Taysha Gene Therapies Cash Flow from Operating Activities 2020-2023 | TSHA
Taysha Gene Therapies cash flow from operating activities from 2020 to 2023. Cash flow from operating activities can be defined as a company's cash flows from operations.
Taysha Gene Therapies Annual Cash Flow Ops
(Millions of US $) |
| 2023 |
$-73 |
| 2022 |
$-88 |
| 2021 |
$-117 |
| 2020 |
$-31 |
| 2019 |
$0 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.481B |
$0.015B |
|
Taysha Gene Therapies Inc. is a patient-centric gene therapy company. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company's product pipeline includes TSHA-101, TSHA-118, TSHA-102, TSHA-103 and TSHA-104 which are in clinical stage. Taysha Gene Therapies Inc. is based in Dallas, Texas.
|
